Market Analysts see Alzamend Neuro Inc. [ALZN] gaining to $8. Time to buy?

view original post

Alzamend Neuro Inc. [NASDAQ: ALZN] traded at a high on 11/23/21, posting a 12.89 gain after which it closed the day’ session at $2.14. The company report on September 30, 2021 that Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease.

FDA Agrees to Alzamend’s Plan to Conduct a Combined Phase 1 and 2 Clinical Trial for AL002.


3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, announced that it has received a written response to its meeting request relating to its Type B Pre‑Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (the “FDA”) providing a path for Alzamend’s planned clinical development of AL002. AL002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.

The results of the trading session contributed to over 6660026 shares changing hands. Over the past one week, the price volatility of Alzamend Neuro Inc. stands at 11.88% while the volatility over the past one month is 11.18%.

The market cap for ALZN stock reached $182.97 million, with 84.59 million shares outstanding and 44.53 million shares in the current float. Compared to the average trading volume of 5.30M shares, ALZN reached a trading volume of 6660026 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Alzamend Neuro Inc. [ALZN]?

Ascendiant Capital Markets have made an estimate for Alzamend Neuro Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 01, 2021.

The Average True Range (ATR) for Alzamend Neuro Inc. is set at 0.24 The Price to Book ratio for the last quarter was 11.92, with the Price to Cash per share for the same quarter was set at 0.18.

How has ALZN stock performed recently?

Alzamend Neuro Inc. [ALZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.51.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALZN stock in for the last two-week period is set at 45.55, with the RSI for the last a single of trading hit 46.05, and the three-weeks RSI is set at 43.84 for Alzamend Neuro Inc. [ALZN]. The present Moving Average for the last 50 days of trading for this stock 2.3900, while it was recorded at 2.1100 for the last single week of trading.

Alzamend Neuro Inc. [ALZN]: Deeper insight into the fundamentals

Return on Total Capital for ALZN is now -312.43, given the latest momentum, and Return on Invested Capital for the company is -356.06. Return on Equity for this stock declined to -356.06, with Return on Assets sitting at -213.54. When it comes to the capital structure of this company, Alzamend Neuro Inc. [ALZN] has a Total Debt to Total Equity ratio set at 16.66. Additionally, ALZN Total Debt to Total Capital is recorded at 14.28, with Total Debt to Total Assets ending up at 11.51.

Reflecting on the efficiency of the workforce at the company, Alzamend Neuro Inc. [ALZN] managed to generate an average of -$2,523,283 per employee.Alzamend Neuro Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.40 and a Current Ratio set at 11.40.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for Alzamend Neuro Inc. [ALZN]

There are presently around $1 million, or 6.70% of ALZN stock, in the hands of institutional investors. The top three institutional holders of ALZN stocks are: TWO SIGMA INVESTMENTS, LP with ownership of 172,913, which is approximately New of the company’s market cap and around 0.70% of the total institutional ownership; SASSICAIA CAPITAL ADVISERS LLC, holding 93,762 shares of the stock with an approximate value of $0.2 million in ALZN stocks shares; and SUSQUEHANNA INTERNATIONAL GROUP, LLP, currently with $0.2 million in ALZN stock with ownership of nearly 61.803% of the company’s market capitalization.

Positions in Alzamend Neuro Inc. stocks held by institutional investors increased at the end of December and at the time of the December reporting period, where 16 institutional holders increased their position in Alzamend Neuro Inc. [NASDAQ:ALZN] by around 504,880 shares. Additionally, 6 investors decreased positions by around 155,569 shares, while 0 investors held positions by with 15,476 shares. The mentioned changes placed institutional holdings at 644,973 shares, according to the latest SEC report filing. ALZN stock had 11 new institutional investments in for a total of 422,048 shares, while 5 institutional investors sold positions of 76,240 shares during the same period.